A monster discovery deal between AbbVie and Google’s Calico gets a new lease on the lab, with $1B more to back aging research
Nearly 4 years after AbbVie and Google’s fledgling Calico stepped up to the altar of drug science and committed themselves to a $1.5 billion partnership on developing a pipeline of anti-aging drugs, they’ve decided to renew their vows.
And this time they’re backing it up with a joint $1 billion pledge — $500 million each — to keep the alliance going for some years to come, with an eye to slowly stepping up the relationship in a move toward the clinic. In a rare public display of affection, the two companies are touting the advance of more than two dozen late discovery projects, with a special focus on cellular stress that they believe has some profound long term implications for human health.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters